Comparative Pharmacology
Head-to-head clinical analysis: BUSULFEX versus HEPZATO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSULFEX versus HEPZATO.
BUSULFEX vs HEPZATO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Busulfan is a bifunctional alkylating agent that cross-links DNA, leading to inhibition of DNA replication and cell death.
HEPZATO (melphalan) is a nitrogen mustard alkylating agent that crosslinks DNA strands, inhibiting DNA replication and transcription, leading to cell death.
Busulfan 0.8 mg/kg IV every 6 hours for 4 days (total 16 doses) or 3.2 mg/kg IV once daily for 4 days, based on ideal body weight or actual body weight (whichever is lower).
Melphalan 3 mg/kg ideal body weight via hepatic artery infusion over 15-30 minutes followed by hemofiltration, administered once per treatment cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours (range: 1.5-4.0 hours) in adults. In children, half-life is shorter (~1.4 hours). Clinically, this supports high-dose, fractionated dosing regimens (e.g., every 6 hours) to maintain therapeutic levels.
The terminal elimination half-life of melphalan is approximately 1.5 hours following intravenous administration. This short half-life necessitates regional delivery (hepatic arterial infusion) to achieve high local concentrations with limited systemic exposure.
Primarily hepatic metabolism via conjugation with glutathione, followed by renal excretion of metabolites. Less than 2% of the parent drug is excreted unchanged in urine. Fecal excretion is negligible.
HEPZATO (melphalan hydrochloride) for injection is renally eliminated; approximately 20-30% of the administered dose is excreted unchanged in the urine over 24 hours. The major metabolites are hydrolysis products, which are also excreted renally. Biliary/fecal elimination accounts for less than 10% of the dose.
Category C
Category C
Alkylating Agent
Alkylating Agent